These include p16, HPV, and ctHPVDNA in the HPV-positive population; EBV and anti-EBV antibodies in the EBV-positive population; and p53, EGFR, and PDL1 in the non-virally induced cancer population; with a myriad of other biomarkers being studied. This evidence concerns the gene CDKN2A and cancer.